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ity, mortality from malignant neoplasms, non-Hodgkin’s 
lymphoma and digestive system disorders were signifi -
cantly higher in gluten sensitive patients compared to 
the Northern Ireland population.
CONCLUSION: Patients with coeliac disease or gluten 
sensitivity had higher mortality rates than the Northern 
Ireland population. This association persists more than 
one year after diagnosis in patients testing positive for 
anti-gliadin antibodies. Breast cancer is signifi cantly re-
duced in the cohort of patients with gluten sensitivity.
© 2007 The WJG Press. All rights reserved.
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INTRODUCTION
Coeliac disease (CD) is an autoimmune disorder character-
ised by infl ammation and villous atrophy of  the small in-
testine, resulting in the malabsorption of  vitamins and nu-
trients. It is caused by an immune response to wheat gluten 
(gliadin). Ireland is thought to have one of  the highest 
incidences of  CD in the world with a prevalence in North-
ern Ireland of  at least 1 person per 122 in the population[1]. 
Diagnosis is normally confi rmed by duodenal biopsy; how-
ever, highly sensitive and specifi c blood tests for CD are 
available including the transglutaminase antibody test (93% 
sensitive, > 99% specific) and the endomysial antibody 
(EMA) test (93% sensitive, > 98% specifi c)[2]. Another test 
the anti-gliadin antibody (AGA) test is not as sensitive or 
specifi c for CD. It is a measure of  the immune response to 
gliadin and may detect people with gluten sensitivity who 
don’t have clinically detectable CD. Patients testing positive 
for CD are advised to adhere to a strict gluten free diet for 
life[3,4] to avoid symptoms such as diarrhoea, anaemia and 
weight loss associated with this condition.
In addition to the signifi cant morbidity that can be as-
sociated with this condition, CD is thought to be associ-
ated with an increased risk of  malignancy and mortality. 
A recent European multi-centre study reported more than 
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Abstract
AIM: To determine the risk of malignancy and mortality 
in patients with a positive endomysial or anti-gliadin an-
tibody test in Northern Ireland.
METHODS: A population-based retrospective cohort 
study design was used. Laboratory test results used 
in the diagnosis of coeliac disease were obtained from 
the Regional Immunology Laboratory, cancer statistics 
from the Northern Ireland Cancer Registry and mortal-
ity statistics from the General Registrar Offi ce, Northern 
Ireland. Age standardized incidence ratios of malignant 
neoplasms and standardized mortality ratios of all-cause 
and cause-specifi c mortality were calculated.
RESULTS: A total of 13 338 people had an endomysial 
antibody and/or an anti-gliadin antibody test in Northern 
Ireland between 1993 and 1996. There were 490 pa-
tients who tested positive for endomysial antibodies and 
they were assumed to have coeliac disease. There were 
1133 patients who tested positive for anti-gliadin anti-
bodies and they were defi ned as gluten sensitive. Ma-
lignant neoplasms were not signifi cantly associated with 
coeliac disease; however, all-cause mortality was signifi -
cantly increased following diagnosis. The standardized 
incidence and mortality ratios for non-Hodgkin’s lym-
phoma were increased in coeliac disease patients but did 
not reach statistical signifi cance. Lung and breast cancer 
incidence were signifi cantly lower and all-cause mortal-
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a three-fold increased risk of  non-Hodgkin’s Lymphoma 
(NHL) in patients with clinically diagnosed CD[5]. Other 
studies have also reported an increased incidence and/or 
mortality of  NHL in patients with CD[4,6-12]. Estimates of  
the standardised incidence ratio range from 3.3[5] to 18.0[10], 
although Card et al suggest that the risk of  NHL is at the 
lower end of  these estimates[7].
CD has been associated with an increased risk of  other 
cancers including cancers of  the gastrointestinal tract[7-9,11], 
in particular cancers of  the small intestine[7,9-11]. However, 
West et al in a recent study including 4732 people with 
CD found that most cancers, except NHL, were reported 
within one year of  diagnosis of  CD[8].
Studies have also reported that CD may be associated 
with reduced risks of  some cancers including breast can-
cer[8,11,13] although the reason for this association remains 
unknown. West et al[8] reported that lung cancer was less 
common in patients with CD with one possible explana-
tion of  the proposed protective effect of  cigarette smok-
ing[14].
Overall, mortality was higher in patients with CD 
compared to the population[8,10,15]. Metzger et al reported 
a standardised mortality ratio (SMR) of  all-cause mortal-
ity of  2.53 (95% CI 1.50-4.25) with an increased mortality 
from malignant neoplasms[15]. West et al[8] observed that the 
association between all-cause mortality and CD remained 
signifi cant more than one year after diagnosis.
The aim of  this study was to identify the incidence of  
malignancy and mortality in patients with CD (positive 
EMA test) or patients with gluten sensitivity (positive AGA 
test) in a retrospective cohort study in Northern Ireland.
MATERIALS AND METHODS
Exposure measurement
A serological dataset of  all patients investigated for 
suspected coeliac disease tested for IgA EMA and/or 
IgA AGA between 1993 and 1996 was obtained from 
the Regional Immunology Laboratory, Royal Group of  
Hospitals, Belfast. If  patients had EMA/AGA tests on 
more than one occasion their date of  inclusion in the 
study was the date of  the fi rst positive EMA or AGA re-
sult. Duplicates were removed and records with no date of  
birth excluded. Cases were defi ned as patients with ‘coeliac 
disease’ (positive EMA result) or ‘patients with an intol-
erance to gliadin in the diet’ (positive AGA, result more 
than 100 × 103 EU/L). No information was available on 
the EMA test results for 4585 patients who had an AGA 
test. These patients were excluded from the AGA positive, 
EMA negative analysis.
Outcome measurement - incidence
Researchers within the Northern Ireland Cancer Registry 
(NICR)-LAA, LJM, CF; who are experienced in the 
procedures involved in linking datasets, used forename, 
surname, date of  birth and when available hospital number 
or General Practitioner name to match patients in the 
serological database to patients within the NICR database. 
EMA and AGA positive patients were followed-up for 
between 7 and 11 years until the end of  December 2003. 
Exact and “fuzzy” matching algorithms were used to link 
patients in the two databases. “Fuzzy” matching used 
phonetic codes for the forename and surname to match 
similar sounding names which had different spellings 
(i.e. Smyth and Smith). If  dates of  birth were similar (i.e. 
01/03/1975 and 03/01/1975) they were considered as 
potential matches. All “fuzzy” and potential matches were 
checked manually using all available information before 
being included in the study.
The main outcome measures were classified accord-
ing to the International Classification of  diseases (ICD) 
9 before 2002 and ICD 10 thereafter: (1) Any malignant 
neoplasm (ICD 9: 140-208, 230-234; ICD 10: C00-C97); (2) 
NHL (ICD 9: 200, 202; ICD 10: C82-C85); (3) Gastroin-
testinal tract cancer (ICD 9: 150-154; ICD 10: C15-C21); (4) 
Small bowel cancer (ICD 9: 152; ICD 10: C17); (5) Lung 
cancer (ICD 9: 162-163; ICD 10: C34); (6) Breast cancer 
(ICD 9: 174-175; ICD 10: C50); (7) Prostate cancer (ICD 9: 
185; ICD 10: C61); (8) Liver cancer (ICD 9: 155; ICD 10: 
C22).
Outcome measurement - mortality
The serological database was also linked by forename, 
surname and date of  birth to death records held by the 
Registrar General’s Offi ce (GRO), Northern Ireland until 
the end of  December 2003. These files contain cause-
specific mortality data on all deaths occurring within 
Northern Ireland. Exact matching and “fuzzy” matching 
algorithms were used and potential matches were checked 
manually. Outcome measures included all-cause and cause-
specific mortality. Ethical committee approval for this 
study was obtained from the Research Ethics Committee 
of  the Queen’s University Belfast to match the databases. 
Statistical analysis
Total person-years of  follow-up for the cohort of  patients 
with a positive EMA test and for the cohort of  patients 
with a positive AGA test were calculated by collating the 
person-years of  follow-up for each patient from the date 
of  entry into the cohort (1993 to 1996) until the date of  
death or 31st December 2003, whichever was earlier.
Indirect standardizat ion was used to calculate 
standardised incidence ratios (SIRs) for all malignant 
neoplasms and for each cancer type (including NHL, 
gastrointestinal cancers, small bowel, breast, prostate, liver 
and lung cancer) for patients with a positive EMA test, 
for patients with a positive AGA test and for patients with 
a positive AGA test but a negative EMA test. The SIRs 
were calculated by taking the total number of  observed 
cancers within the cohort of  patients with a positive EMA 
or AGA test and dividing this by the expected number 
of  cancers, calculated by applying age and sex-specific 
incidence rates within the Northern Ireland population 
to each cohort. CIs were estimated using the Poisson 
distribution. Standardised mortality ratios were calculated 
in a similar manner to the SIRs using all and cause-specifi c 
mortality figures obtained from the General Registrar 
Offi ce, Northern Ireland.
RESULTS
Of  the 13 338 patients in Northern Ireland who under-
went EMA and/or AGA tests between 1993 and 1996 490 
were EMA positive (5.6% of  EMA tests), 1,133 AGA pos-
itive (8.5% of  all AGA tests) and 456 patients were AGA 
positive and EMA negative (5.2% of  those tested for both 
EMA and AGA) (Table 1).
The average age (age range) of  patients with a positive 
EMA or AGA test were 45 (0-88) years and 50 (0-91) years 
respectively. Included in the database were 46 children (< 
18 years) with a positive EMA test (9.2% of  cohort) and 
71 children with a positive AGA test (6.3% of  cohort). In 
total 68.2% of  EMA positives and 63.2% of  AGA posi-
tives were male. The average AGA score in those testing 
positive was 215.4 × 103 EU/L (range 100-1163 × 103 
EU/L).
Standardised incidence ratios-EMA
In total 24 (4.90%) of  the EMA positive patients devel-
oped a malignant neoplasm during the follow-up period, 6 
of  which were diagnosed within 12 mo of  the test. There 
were no signifi cant associations between a positive EMA 
test and developing a malignant neoplasm (Table 2). Due 
to the small number of  EMA positive patients developing 
malignancy the confidence intervals for the site specific 
cancers are large resulting in no significant associations 
despite a raised SIR being found for NHL [SIR 7.47 (95% 
CI 0.00-17.83)], small bowel cancer [SIR 23.33 (95% CI 
0.00-69.07)] and primary liver cancer [SIR 31.62 (95% CI 
0.00-75.45)]. Lung cancer appeared to be less common in 
EMA positive patients than in the Northern Ireland popu-
lation [SIR 0.39 (95% CI 0-1.14)].
Standardised incidence ratios - AGA
In total 96 (8.47%) of  the AGA positive population de-
veloped a malignant neoplasm. There were no signifi cant 
associations between a positive AGA result and the devel-
opment of  malignant neoplasms (Table 2). However, ma-
lignancy was signifi cantly raised in the AGA positive, EMA 
negative group [SIR 1.82 (95% CI 1.39-2.26)] (Table 2). 
This association was confi ned to males, SIR 2.90 (95% CI 
2.11-3.69), and remained signifi cant 6 and 12 mo after the 
AGA test, SIR 2.16 (95% CI 1.48-2.84) and SIR 1.91 (95% 
CI 1.27-2.55), respectively. Overall incidence of  malignant 
neoplasms occurring 6 and 12 mo after the AGA test were 
signifi cantly reduced in females SIR 0.60 (95% CI 0.27-0.92) 
and SIR 0.51 (95% CI 0.19-0.83) respectively. There was 
a signifi cant inverse relationship between lung and breast 
cancer and a positive AGA result; however, only breast 
cancer was signifi cantly reduced in the AGA positive EMA 
negative group. The SIR was raised for both small bowel 
and liver cancer but the results were not statistically signifi -
cant.
Standardised mortality ratios - EMA
Overall mortality was signifi cantly higher in the EMA posi-
tive population compared to the Northern Ireland popula-
tion (Table 3). However, the statistically signifi cant associa-
tion did not remain when deaths within 6 mo or 1 year of  
the EMA test were excluded from the analysis. Although 
there were no other statistically significant association’s 
mortality from NHL, endocrine deaths and urinary deaths 
appeared increased.
Standardised mortality ratios - AGA
Overall, mortality was higher in the AGA positive and in 
the AGA positive/EMA negative populations than in the 
Northern Ireland population (Table 3). This association 
Table 1  Number of EMA and AGA positive and negative patients
AGA +ve EMA -ve EMA Not recorded Total
+ve 275   456   402    1133 
-ve 215 7807 4183 12 205
Total 490 8263 4585 13 338
Table 2  Standardised incidence ratio (SIR) of malignancies
          EMA +ve           AGA +ve     AGA +ve, EMA -ve
n  Expected
 n
  SIR 
 (95% CI)
n  Expected
 n
 SIR 
 (95% CI)
n  Expected
 n
  SIR 
  (95% CI)
All malignancies 24 25.41   0.94 (0.57-1.32) 96 86.13 1.11 (0.89-1.34) 68 37.28   1.82 (1.39-2.26)
All malignancies 
(> 6 mo after diagnosis) 
20 24.26   0.82 (0.46-1.19) 75 86.05 0.87 (0.67-1.07) 52 39.84        1.31 (0.95-1.66)
All malignancies 
(> 12 mo after diagnosis)     
18 24.24   0.74 (0.40-1.09) 67 85.94 0.78 (0.59-0.97) 44 37.15   1.18 (0.83-1.53) 
Non-Hodgkin’s lymphoma   2   0.27   7.47 (0.00-17.83)   6   2.59 2.32 (0.46-4.17)   3   0.52   5.76 (0.00-12.28) 
Gastrointestinal cancer   4   2.97   1.35 (0.03-2.67) 14 11.70 1.20 (0.57-1.82)   9   5.24   1.72 (0.60-2.84)
Small intestine   1   0.04 23.33 (0.00-69.07)   1   0.14 7.28 (0.00-21.54)   1   0.06 15.51 (0.00-45.90) 
Lung cancer   1   2.60   0.39 (0-1.14)   5   9.98 0.50 (0.06-0.94)   4   4.51   0.89 (0.02-1.76)
Breast cancer   4   3.92   1.02 (0.02-2.02)   5 10.53 0.47 (0.06-0.89)   1   4.09   0.24 (0.00-0.72)
Prostate cancer   2   1.12   1.78 (0.00-4.24)   8   6.30 1.27 (0.39-2.15)   3   3.13   0.96 (0.00-2.04)
Liver cancer   2   0.06 31.62 (0.00-75.45)   3   0.60 5.01 (0.00-10.69)   2   0.27   7.48 (0.00-17.86)
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remained significant even when deaths occurring within 
6 mo and one year of  the test were excluded. Mortality 
caused by malignant neoplasms was also signifi cantly raised 
in both groups as was mortality from digestive system dis-
orders. Mortality from NHL was signifi cantly higher and 
mortality from circulatory system disease was signifi cantly 
lower in the AGA positive group but not in the AGA posi-
tive/EMA negative group.
DISCUSSION
In this retrospective cohort study the incidence of  
malignant neoplasms in patients with CD (positive 
EMA test) was similar to that of  the Northern Ireland 
population. However, patients with gluten sensitivity 
(positive AGA test) had an increased incidence of  
malignant neoplasms within six months of  diagnosis. 
In keeping with the findings of  other studies all cause 
mortality was significantly raised in patients with CD; 
however, this was l imited to the six month period 
following diagnosis. Patients with gluten sensitivity had 
a significantly raised SMR; this association remained 
signifi cant more than 12 mo after diagnosis. Compared to 
the general population breast and lung cancer incidence 
were signifi cantly lower in patients with gluten sensitivity. 
Mortality from malignant neoplasms, NHL and digestive 
system disorders was signifi cantly increased.
The main strength of  this study is its population-based 
design. All patients within Northern Ireland with clinical 
symptoms suspicious of  CD and who also had a positive 
EMA and/or AGA test during the study period (1993 to 
1996) were included. Since a wide spectrum of  patients 
were included in the study the results should be more 
generalisable to patients with gluten sensitivity than the 
results of  studies where CD was diagnosed in hospital or 
at referral centres[9-11,16,17]. It is likely that cases diagnosed as 
hospital in-patients or at referral centres have more severe 
disease and therefore cancer incidence and mortality may 
be higher in this group of  patients than in all CD patients. 
CD may go undetected in the population and without 
screening it is diffi cult to generalise any of  the results to all 
patients with CD within the population.
Population-based registers of  cancer incidence and 
cause-specific mortality facilitated the matching process. 
Incomplete matching of  patients on the serological data-
base to the NICR and/or GRO database may result in an 
underestimation of  the risk of  malignancy and/or mortal-
ity compared to the general population. To minimize the 
possibility of  observer bias the staff  was blinded to the 
positive/negative result status of  the patients during the 
matching process. Cancer incidence and mortality in EMA 
positive, AGA positive and AGA positive/EMA nega-
tive patients were compared to the rates in the Northern 
Ireland population. Other studies have used population-
based controls[8] or population rates for comparison[7,10-12]; 
however, the study by Collin et al used hospital outpatients 
undergoing upper gastrointestinal endoscopy as con-
trols[17]. These patients are likely to have been under inves-
tigation because of  upper gastrointestinal symptoms and 
are unlikely to be representative of  the general population. 
One of  the proposed explanations for previous reports 
of  increased gastrointestinal cancer incidence in CD pa-
tients[7-9,11] is that CD was diagnosed coincidentally when 
the patients were under investigation for tumour related 
symptoms. Several studies have reported cancer incidence 
and/or mortality rates with lag periods of  between 1 and 5 
years[7,10-12,16] after diagnosis of  CD. We, therefore, included 
SIRs and SMRs excluding patients with an event in the 
6-or 12-mo period post diagnosis.
There were 3908 person years of  follow-up for malig-
nancy and 3718 person years of  follow-up for mortality 
in the cohort of  patients with CD. Bias may have been 
introduced by loss to follow-up although emigration rates 
are low in Northern Ireland; data from the GRO (Northern 
Ireland) estimates that less than 0.1% of  the population 
migrated from the province per year during the 1990s[18]. 
One of  the potential weaknesses of  this study was the 
lack of  histological confirmation of  CD. Although it is 
likely that jejunal biopsies were taken from patients with 
a positive EMA test gaining access to these records with-
out patient consent would have required further ethical 
considerations. However, the sensitivity and specifi city of  
the EMA test are high[2] and it is, therefore, likely to give a 
relatively accurate measure of  the incidence of  CD in the 
Table 3  Standardised mortality ratios (SMR) of all cause and cause-specifi c mortality
           EMA +ve             AGA +ve      AGA +ve, EMA -ve
 n Expected
 n
SMR 
 (95% CI)
 n Expected
 n
SMR 
 (95% CI)
 n Expected
 n
SMR 
 (95% CI)
All cause mortality 46 26.01 1.77 (1.26-2.28) 234 101.25 2.31 (2.01-2.61) 114 47.25 2.41 (1.97-2.86)
All cause mortality 
(> 6 mo after diagnosis)
35 25.9 1.35 (0.90-1.80) 184 100.79 1.83 (1.56-2.09)   85 46.91 1.81 (1.43-2.20)
All cause mortality 
(> 12 mo after diagnosis)     
32 25.91 1.24 (0.81-1.66) 165 100.09 1.65 (1.40-1.90)   75 46.59 1.61 (1.25-1.97)
Malignant neoplasms   9   7.05 1.28 (0.44-2.11)   52   32.28 1.61 (1.17-2.05)   27 14.55 1.86 (1.16-2.56)
NHL deaths   2   0.29 6.89 (0.00-16.44)     8     1.12 7.12 (2.18-12.05)     3   0.51 5.88 (0.00-12.53)
Endocrine deaths   1   0.16 6.10 (0.00-18.07)     2     0.24 8.19 (0.00-19.53)     1   0.58 1.73 (0.00-5.14)
Nervous system   1   0.25 3.96 (0.00-11.72)     2     2.92 0.69 (0.00-1.63)     1   2.92 0.34 (0.00-1.01)
Circulatory system   9 12.11 0.74 (0.26-1.23)   42   59.95 0.70 (0.49-0.91)   22 28.65 0.77 (0.45-1.09)
Respiratory system   3   2.67 1.12 (0.00-2.40)   35   25.18 1.39 (0.93-1.85)     2   1.45 1.38 (0.00-3.29)
Digestive system disorders   2   0.58 3.42 (0.00-8.17)   19     4.12 4.61 (2.54-6.68)   10   1.90 5.26 (2.00-8.52)
Anderson LA et al. Coeliac disease: Malignancy and mortality                             149
www.wjgnet.com
cohort. The EMA test detects antibodies to an antigen (tis-
sue transglutaminase) present in the endomysial lining of  
smooth muscle cells. The AGA test measures antibodies 
to gliadin which do not remain in patients who adhere to 
a strict gluten free diet. The assay will become negative if  
the patient is compliant with a gluten free diet. Therefore 
some patients with CD may not be detected within the 
cohort. The study by Logan et al showed that cancer inci-
dence was decreased in those who were diagnosed early 
and placed on a gluten-free diet[13]. If  this is the case then 
the incidence of  malignancy in CD patients may be lower 
than reported. However, we had no way to determine 
whether or not the patients included in the study adhered 
to a strict gluten-free diet.
Another issue is that multiple comparisons may in-
flate the possibility of  a Type 1 error occurring (i.e. the 
apparent association resulting by chance). However, only 
malignant neoplasms/causes of  mortality where there had 
been a previous association or where there was an a priori 
hypothesis were investigated.
One issue with using these datasets and using a ret-
rospective cohort design is that potential confounding 
variables were not collected at the time the cohort was 
established and therefore these could not be adjusted for 
in the analyses. Potential confounding variables could in-
clude co-existing medical conditions, smoking, body mass 
index, diet, age, sex, etc. For example, diabetes is associated 
with CD and possibly with endocrine deaths which were 
non-significantly raised and smoking which is less com-
mon in patients with CD[14] is associated with lung cancer 
incidence. There was a signifi cantly reduced risk of  lung 
cancer in patients with a positive AGA test and a non-
significant reduced risk in patients with a positive EMA 
test. West et al was the only study to attempt to adjust for 
potential confounding variables[8]. Adjusting for BMI and 
smoking did not dramatically alter the observed associa-
tions; however, the authors suggest that data on potential 
confounders may be incomplete as it was obtained from 
routinely collected information.
Although some AGA positive/EMA negative patients 
may have CD there were a larger number that were AGA 
positive than expected according to the sensitivity of  the 
EMA test. Therefore, some of  these patients may be glu-
ten sensitive but as yet have no damage to the endomycial 
muscle. If  this is the case then this is the fi rst study to in-
vestigate the risk of  malignancy and mortality in this group 
of  patients, who were excluded from the recent large study 
by West et al[8]. Mortality was signifi cantly increased in this 
group of  patients and remained elevated more than one 
year after the positive AGA test. Mortality from digestive 
system disorders was increased which was not surprising as 
a positive AGA test may be a marker for other gastrointes-
tinal disorders. Interestingly, it is in this group of  patients 
that breast cancer appears to be reduced. Other studies 
have reported reduced risks of  breast cancer in patients 
with CD[8,11,13] although there were no signifi cant associa-
tions between breast cancer and a positive EMA test in 
this study. Although the reason(s) for this association re-
main unknown Askling et al suggest that the reduced risk 
of  breast cancer may be a consequence of  immune system 
dysfunction[11].
The size of  the current study is smaller than the more 
recently published studies e.g. the study by West et al[8] who 
used the General Practice Research Database which had 
4,732 CD patients. Malignancy was increased in patients 
in the fi rst year after diagnosis but not beyond one year 
of  follow-up. In the current study malignancy was not 
increased in patients with a positive EMA test but was in 
patients with a positive AGA test. Other studies have also 
reported no overall increased risk of  malignancy in CD 
patients[7,16]. The size of  the current study meant that there 
was insuffi cient power to detect any associations between 
cancer type and CD. However, the risk of  NHL appeared 
to be increased which is in keeping with the results of  
other studies[3-5,7-12]. There was a signifi cant increased risk 
of  NHL deaths in patients with a positive AGA test. This 
group of  patients is likely to include some patients with 
CD as there were a number of  patients that had no EMA 
record in the database.
Malignancy and mortality were not significantly 
increased in patients with CD more than one year after 
diagnosis; however, overall mortality and mortality from 
malignant neoplasms were increased in patients who 
were gluten sensitive with a negative EMA test. If  these 
patients do not have the histological characteristics of  
CD then it is important to determine the cause of  the 
increased mortality. If  this is limited to other digestive 
system disorders then patients with a negative EMA test 
but with symptoms should be further investigated for 
other digestive system disorders. Further investigations 
into this area are warranted to determine if  it is gluten 
sensitivity that is associated with increased mortality and 
malignancy or to determine if  it is just a marker for other 
gastrointestinal conditions. 
In addition, it is important to determine the risk of  
malignancy and mortality in patients with a histological 
confirmation of  CD. This study could be extended 
further by collecting pathology reports on all patients 
within the study and looking for evidence of  villous 
atrophy. Information on confounding variables such as 
smoking status could also be collected. However, it is 
unlikely that patients could be approached because of  data 
confi dentiality issues. It is possible that cancer incidence 
and mortality change depending on the length of  time 
since diagnosis. Therefore, an extension to this study 
would be to follow-up the patients for a longer period of  
time. The association with reduced breast cancer incidence 
is interesting and further studies to investigate this 
association may identify factors that are associated with 
reduced breast cancer incidence. 
REFERENCES
1 Johnston SD, Watson RG, McMillan SA, Sloan J, Love AH. 
Prevalence of coeliac disease in Northern Ireland. Lancet 1997; 
350: 1370
2 Lewis NR, Scott BB. Systematic review: the use of serology 
to exclude or diagnose coeliac disease (a comparison of the 
endomysial and tissue transglutaminase antibody tests). 
Aliment Pharmacol Ther 2006; 24: 47-54
3 Holmes GK, Prior P, Lane MR, Pope D, Allan RN. Malignancy 
in coeliac disease--effect of a gluten free diet. Gut 1989; 30: 
333-338
150      ISSN 1007-9327       CN 14-1219/R      World J Gastroenterol        January 7, 2007       Volume 13      Number 1
www.wjgnet.com
4 Loftus CG, Loftus EV Jr. Cancer risk in celiac disease. 
Gastroenterology 2002; 123: 1726-1729
5 Mearin ML, Catassi C, Brousse N, Brand R, Collin P, Fabiani 
E, Schweizer JJ, Abuzakouk M, Szajewska H, Hallert C, Farre 
Masip C, Holmes GK. European multi-centre study on coeliac 
disease and non-Hodgkin lymphoma. Eur J Gastroenterol 
Hepatol 2006; 18: 187-194
6 Smedby KE, Akerman M, Hildebrand H, Glimelius B, Ekbom 
A, Askling J. Malignant lymphomas in coeliac disease: 
evidence of increased risks for lymphoma types other than 
enteropathy-type T cell lymphoma. Gut 2005; 54: 54-59
7 Card TR, West J, Holmes GK. Risk of malignancy in diagnosed 
coeliac disease: a 24-year prospective, population-based, 
cohort study. Aliment Pharmacol Ther 2004; 20: 769-775
8 West J , Logan RF, Smith CJ , Hubbard RB, Card TR. 
Malignancy and mortality in people with coeliac disease: 
population based cohort study. BMJ 2004; 329: 716-719
9 Green PH, Fleischauer AT, Bhagat G, Goyal R, Jabri B, Neugut 
AI. Risk of malignancy in patients with celiac disease. Am J 
Med 2003; 115: 191-195
10 Peters U, Askling J, Gridley G, Ekbom A, Linet M. Causes of 
death in patients with celiac disease in a population-based 
Swedish cohort. Arch Intern Med 2003; 163: 1566-1572
11 Askling J, Linet M, Gridley G, Halstensen TS, Ekstrom K, 
Ekbom A. Cancer incidence in a population-based cohort 
of individuals hospitalized with celiac disease or dermatitis 
herpetiformis. Gastroenterology 2002; 123: 1428-1435
12 Corrao G, Corazza GR, Bagnardi V, Brusco G, Ciacci C, 
Cottone M, Sategna Guidetti C, Usai P, Cesari P, Pelli MA, 
Loperfi do S, Volta U, Calabro A, Certo M. Mortality in patients 
with coeliac disease and their relatives: a cohort study. Lancet 
2001; 358: 356-361
13 Logan RF, Rifkind EA, Turner ID, Ferguson A. Mortality in 
celiac disease. Gastroenterology 1989; 97: 265-271
14 Suman S, Williams EJ, Thomas PW, Surgenor SL, Snook JA. 
Is the risk of adult coeliac disease causally related to cigarette 
exposure? Eur J Gastroenterol Hepatol 2003; 15: 995-1000
15 Metzger MH, Heier M, Maki M, Bravi E, Schneider A, Lowel 
H, Illig T, Schuppan D, Wichmann HE. Mortality excess 
in individuals with elevated IgA anti-transglutaminase 
antibodies: the KORA/MONICA Augsburg cohort study 
1989-1998. Eur J Epidemiol 2006; 21: 359-365
16 Viljamaa M, Kaukinen K, Pukkala E, Hervonen K, Reunala T, 
Collin P. Malignancies and mortality in patients with coeliac 
disease and dermatitis herpetiformis: 30-year population-
based study. Dig Liver Dis 2006; 38: 374-380
17 Collin P, Reunala T, Pukkala E, Laippala P, Keyrilainen O, 
Pasternack A. Coeliac disease--associated disorders and 
survival. Gut 1994; 35: 1215-1218
18 Northern Ireland Statistics and Research Agency. Northern 
Ireland Migration Flows 1991-2005. Population statistics 
online, cited 2006-18-08. Available from: URL: http://www.
nisra.gov.uk/archive/demography/population/net_migratio
n_by_ageandsex05.xls
S- Editor  Yang XX    L- Editor  Rippe RA    E- Editor  Liu WF
Anderson LA et al. Coeliac disease: Malignancy and mortality                             151
www.wjgnet.com
